2017
DOI: 10.1016/j.gore.2017.10.004
|View full text |Cite
|
Sign up to set email alerts
|

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user

Abstract: BackgroundTamoxifen is a medication often used for the treatment and prevention of breast cancer. It is classically associated with several gynecological side effects to include a thickened endometrial stripe, increased uterine polyp formation, and an increased risk of uterine cancer. Rarely tamoxifen use has been associated with proliferation of endometriosis often severe enough to mimic a late-stage gynecologic malignancy.CaseA 62-year-old Gravida 0 postmenopausal female with a medical history of severe obes… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
10
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 13 publications
0
10
0
Order By: Relevance
“…The reports about tamoxifen causing the proliferation of existing EMs are rare and most of the patients are menopausal and older than 50 years old. 5 The rebound of GnRH agonist withdrawal more likely occurred in young women, 2 but few were reported without exposure to any of these drugs.…”
Section: Discussionmentioning
confidence: 99%
“…The reports about tamoxifen causing the proliferation of existing EMs are rare and most of the patients are menopausal and older than 50 years old. 5 The rebound of GnRH agonist withdrawal more likely occurred in young women, 2 but few were reported without exposure to any of these drugs.…”
Section: Discussionmentioning
confidence: 99%
“…Plasma concentrations of 17b-estradiol were low (20-40 pg/ml); cyst fluid concentrations were 80 pg/ml returning to normal after GnRha treatment [50]. A series of reports describe progressive endometriosis in women taking tamoxifen [51][52][53][54].…”
Section: A Systematic Review Of Clinically Progressive Postmenopausal Endometriosis Without Estrogen Intake or Increased Productionmentioning
confidence: 99%
“…(Table 4). [11] 43 post vaginal fornix / prolonged menstruation 3 MRI CEA 2017 Zhuang, L [12] 62 ureteric tamoxifen gross hematuria 1.5⋅1.0 CA 125 37.6 2017 Han, K [13] 58 Colonic / uterine bleeding 13x7x4 / 2017 Iida, Y [14] 44 ovary / müllerianosis of the pelvic lymph node 3.0 MRI 2017 Jaegle, WT [15] 62 endocervical, uterine serosal surface tamoxifen pelvic mass 1. individual in ureter, fallopian tubes, greater omentum and retroperitoneal region [3][4][5][6]7,9] . As shown in Table 1, ovarian PEM accounted for 4 of the 7 cases in this group, followed by uterine serosal and cervical PEM.…”
Section: Other Cases Reported These Yearsmentioning
confidence: 99%
“…Parker [2] believed that PEM was common in elderly women, and 60% of the 24 PEM patients they observed were older than 50 years old (23-78 years old), with multifocal lesions, and most of the cases had a history of EMs. In addition, 13 international cases reported in the past 5 years, aged 20-62 (51.14±3.78) years old (as Table 4) [10][11][12][13][14][15][16][17][18][19][20][21] , were summarized. Gunawardane DN reported a 50-year-old female had a hysterectomy and bilateral salpingo-oophorectomy for adenomyosis, uterine leiomyomas, ovarian and cervical endometriosis.…”
Section: Other Cases Reported These Yearsmentioning
confidence: 99%